Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly
MONDO:0017346A rare form of diffuse large B-cell lymphoma occurring most commonly in patients over the age of 50 (usually between 70-75 years of age), without overt immunodeficiency, and presenting with nodal and extranodal involvement (in sites such as the stomach, lung, skin and pancreas) and B symptoms (fever, night sweats, weight loss). The tumor is characterized by an aggressive course and a short survival rate.
Also known as: EBV Positive diffuse large B-cell lymphoma of the elderly, EBV-Positive diffuse large B-cell lymphoma, NOS, EBV-positive DLBCL of the elderly, Epstein-Barr Virus Positive diffuse large B-cell lymphoma of the elderly, Senile EBV-associated B-cell lymphoproliferative disorder, age-related EBV Positive B-cell lymphoproliferative disorder
2028 clinical trials for this condition and its sub-types, 23 tagged with Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Phase 3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR T-Cell therapy shows promise against tough lymphoma in major trial
Disease control CompletedThis phase 3 trial tested whether a personalized cell therapy called axicabtagene ciloleucel (Yescarta) works better than standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 359 participants and compared event-fre…
Phase 3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Spinal injection may shield brain from lymphoma spread
Prevention CompletedThis study tested a chemotherapy drug called thiotepa, given via spinal injection, to prevent lymphoma from spreading to the brain or spinal cord in people with high-risk diffuse large B-cell lymphoma (DLBCL). 31 participants received the treatment and were followed for 2 years t…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC